Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 5/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | PARP14 | Q460N5 | 3/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709947 | 0.92 | PARP14 (0.39) | PARP14MAP3K5MAPTMAPK1RORC | |
| SCHEMBL6712091 | 0.92 | PARP14 (0.39) | PARP14MAP3K5MAPTRORC | |
| SCHEMBL6711927 | 0.91 | PARP14 (0.44) | PARP14MAPTTP53RORC | |
| SCHEMBL6713374 | 0.91 | NR1H4 (0.40) | CACNA1HPARP14NLRP3RORC | |
| SCHEMBL6713375 | 0.90 | PARP14 (0.39) | PARP14MAPTTP53 | |
| SCHEMBL6708920 | 0.90 | PARP14 (0.42) | PARP14NLRP3MAPTTP53 | |
| SCHEMBL6707721 | 0.90 | PARP14 (0.41) | PARP14TP53 | |
| SCHEMBL6713731 | 0.90 | PARP14 (0.41) | IDO1PARP14RORC | |
| SCHEMBL6710593 | 0.90 | PARP14 (0.38) | PARP14NLRP3MAP3K5MAPTTP53 | |
| SCHEMBL6713494 | 0.89 | POLB (0.39) | PARP14NLRP3MAPTTP53MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | CACNA1H 2083/4885IDO1 3631/4885PARP14 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.